association of integrin beta1 and c-met in mediating egfr tki gefitinib resistance in non-small cell lung cancer在调节表皮生长因子受体整合素beta1协会和c-met tki耐吉非替尼在非小细胞肺癌.pdfVIP

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer Ju and Zhou Ju and Zhou Cancer Cell International 2013, 13:15 /content/13/1/15 Ju and Zhou Cancer Cell International 2013, 13:15 /content/13/1/15 PRIMARY RESEARCH Open Access Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer Lixia Ju1 and Caicun Zhou2* Abstract Although some patients are initially sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), resistance invariably develops. Therefore, it’s very important to study the molecular mechanism of this resistance. In our previous study we found that integrin beta1 can induce EGFR TKIs resistance in non-small cell lung cancer (NSCLC) cells. Here we analyzed the association of integrin beta1 and c-MET that is a recognized mechanism of EGFR TKIs resistance in NSCLC to demonstrate the mechanism of integrin beta1 related EGFR TKIs resistance. We found that the ligands of integrin beta1 and c-MET could synergistically promote cell proliferation and their inhibitors could synergistically improve the sensitivity to gfitinib, increase apoptosis, and inhibit the downstream signal transduction: focal adhesion kinase (FAK) and AKT. On the other hand, ligand-dependent activation of integrin beta1 could induce EGFR TKIs resistance through activating c-MET and its downstream signals. Thus, it can be concluded that there is crosstalk between integrin beta1 and c-MET and integrin beta1 mediates EGFR TKI resistance associating with c-MET signaling pathway in non-small cell lung cancer. Keywords: Non-small cell lung cancer, Integrin beta1, c